reports
Bio-Path Holdings Announces Publication in Biomedicines
Bio-Path Holdings Announces Publication in Biomedicines Manuscript Highlights Therapeutic Potential of BP1003 in Variety of Cancers Marks Company’s Twenty-Second Peer-Reviewed Publication in Support of its DNAbilize® Technology HOUSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced a publication highlighting the therapeutic potential of BP1003 in a variety of cancer types in th...
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Inv...
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET. An audio webcast of...
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP10...
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase 2 Triple Combination Study of Prexigebersen in Acute Myeloid Leukemia (AML) Supportive Safety and Efficacy Data from Two Assets Validate Potential of DNAbilize® Platform Technology to Treat Most Vulnerable Cancer Patients HOUSTON, Aug. 21, 2024 (GLOBE NE...
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
Bio-Path Holdings Reports Second Quarter 2024 Financial Results Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2024 and provided an update on recent corporate developments. "The first half of 2024 was marked by considerable corporate and clinical progress across the o...
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on...
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and to provide a business overview. To access the live conference ca...
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on...
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 HOUSTON , Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and to provide a business overview. To access the live conference cal...
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Bio-Path Holdings Provides Clinical Update and Expansion Plans Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update on the Company’s clinical progress and plans for expansion. “The Bio-...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted...
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement ...
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules HOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has closed its previously announced private placement for the issuance and sale of an aggregate of 1,809,955 shares of its common stock (or common stock equivalents in lieu thereof)...
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-t...
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules HOUSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,809,955 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to pu...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...
Bio-Path Holdings to Present Data at 2024 European Hematology Associat...
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) HOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2024 European Hematology Association (EHA) Congress, taking place Jun...
Bio-Path Holdings to Present Data at American Society of Clinical Onco...
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) HOUSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeti...
Bio-Path Holdings Reports First Quarter 2024 Financial Results
Bio-Path Holdings Reports First Quarter 2024 Financial Results Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developmen...
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on ...
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 15, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview. To access the live conference call, plea...
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered D...
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 375,000 shares of its common stock at a purchase p...
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offer...
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.22...
Bio-Path Holdings Announces Successful Completion of Higher Dose Secon...
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 Protein HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announ...
Bio-Path Holdings Expands Global Patent Portfolio
Bio-Path Holdings Expands Global Patent Portfolio Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform HOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the receipt of newly issued patents in Mexico, Australia and Japan, and updated investors on the extent of its global intellectual property portfolio. Bio-Path has expanded its intellectual pr...
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Bio-Path Holdings Provides 2024 Clinical and Operational Update Clinical Advances Across Multiple Programs with Several Milestones HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024. “The new year is off to a strong start as we build off positive data generated in 2023 that compel us to advance these studies as quickly ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.